On Monday, Health care stocks were sharply down, with the NYSE Health Care Sector Index losing 0.6% and shares of health care companies in the S&P 500 also dipped 0.6% as a group.
Ultimate Loser From Healthcare Sector:
Among healthcare sector, a biotech company, Ardelyx, Inc. (NASDAQ:ARDX) was ultimate loser for the last day’s trade, as it declined 28.73% to settle at $19.25, soon after a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, recently declared that AstraZeneca’s 161-patient Phase 2b clinical trial evaluating tenapanor in hyperphosphatemic patients with chronic kidney disease on hemodialysis met its primary endpoint by demonstrating a statistically noteworthydose-related decrease in serum phosphate levels for tenapanor-treated patients contrast to patients receiving placebo (p=0.012). It was noted, however, that the rate of diarrhea was distinctly higher than predictable. The overall safety profile remains compriseent with that observed in previous tenapanor trials. In October 2012, Ardelyx reached a partnership with AstraZeneca for the worldwide development and commercialization of tenapanor.
The subtle elements and most recent news about few other Healthcare stocks that dipped in their previous trading session, are portrayed underneath:
In company news, Venaxis Inc(NASDAQ:APPY), declined -14.02% to settle at $0.430, following the financial report.
Venaxis, Inc. develops and commercializes products for unmet diagnostic and therapeutic needs. The company’s research and development activities primarily focus on a human acute appendicitis blood-based test.
Enanta Pharmaceuticals Inc(NASDAQ:ENTA), dropped -10.04% to close at $39.08, soon after a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, declared topline Phase 3 results from the GIFT-1 study, AbbVie’s investigational, all-oral, ribavirin-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan. The primary endpoint of the GIFT-I study was achieved, demonstrating a 95 percent (n= 106/112) sustained virologic response rate at 12 weeks post-treatment (SVR12) in the sub-group of formerly untreated non-cirrhotic adult GT1b Japanese patients who were eligible for therapy with interferon (IFN) and had a high viral load.
Enanta Pharmaceuticals Inc (NASDAQ:ENTA), a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States.
Idera Pharmaceuticals Inc(NASDAQ:IDRA), slumped -6.86% in its last trade, following a clinical-stage biopharmaceutical company developing immune-modulating and gene silencing therapies for cancer and rare diseases, declared the selections of R. Clayton Fletcher as Senior Vice President, Business Development and Strategic Planning, and Jim Baker as Executive Director, Market Development.
Idera Pharmaceuticals Inc(NASDAQ:IDRA), a clinical stage biotechnology company, is engaged in the discovery and development of novel therapeutics that modulate immune responses through toll-like receptors (TLRs) in the United States.
Amicus Therapeutics, Inc.(NASDAQ:FOLD), descended -5.85% to close at $7.24, after a biopharmaceutical company at the forefront of rare and orphan diseases, declared that 2 oral presentations and 6 posters highlighting its development programs for lysosomal storage diseases will be included at the 11th Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD), to be held February 9-13, 2015 in Orlando, FL.
Amicus Therapeutics, Inc.(NASDAQ:FOLD), a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases.
